- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05509010
AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)
AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)
Study Overview
Status
Intervention / Treatment
Detailed Description
Coronary artery disease (CAD), a blockage of the blood vessels, affects 6% of the general population and up to 20% of those over 65 years of age. CAD is a leading cause of cardiac mortality in Singapore and worldwide, with 19% of deaths in Singapore due to CAD (MOH website).
Numbers of CAD cases are increasing due to ageing and the higher prevalence of contributary diseases such as diabetes. Computed Tomography Coronary Angiography (CTCA) is the first-line investigation for CAD as indicated by the National Institute for Clinical Excellence (NICE) guidelines. Recent Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) and Scottish Computed Tomography of the Heart (SCOT-HEART) trials support CTCA as the dominant means for evaluating coronary anatomy and physiology as it increases diagnostic certainty, improves efficiency of triage to invasive catheterization and reduces radiation exposure when compared to functional stress testing.
Currently, CAD report generation requires 3-6 hours of a CT specialist's time to annotate scans, with inter-observer variability of 20%. In addition, there is no effective singular toolkit to analyse Agatston scores (a measure of calcified CAD), severity of stenosis, and plaque characterisation.
These problems have severely constrained the effectiveness of CTCA as a diagnostic and research tool. The investigators plan to build upon Singapore's competitive advantages in artificial intelligence (AI) to provide a solution to these gaps.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Associate Professor Zhong Liang
- Phone Number: +65 6704 2237
- Email: zhong.liang@nhcs.com.sg
Study Contact Backup
- Name: Dr Lohendran Baskaran
- Email: lohendran.baskaran@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital
-
Contact:
- Associate Professor Mark Chan
- Email: mark_chan@nuhs.edu.sg
-
Principal Investigator:
- Associate Professor Mark Chan
-
Singapore, Singapore, 169609
- Recruiting
- National Heart Centre Singapore
-
Contact:
- Assoc. Prof Zhong Liang
- Email: zhong.liang@nhcs.com.sg
-
Principal Investigator:
- Assoc. Prof Zhong Liang
-
Singapore, Singapore
- Recruiting
- Tan Tock Seng Hospital
-
Contact:
- Dr Yew Min Sen
- Email: min_sen_yew@ttsh.com.sg
-
Principal Investigator:
- Dr Yew Min Sen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥21 years old
- Signed informed consent
- Clinically indicated for evaluation by CTCA
Exclusion Criteria:
- Individuals unable to provide informed consent
- Known complex congenital heart disease
- Planned invasive angiography for reasons other than CAD
- Non-cardiac illness with life expectancy < 2 years
- Pregnancy
- Concomitant participation in another clinical trial in which subject is subject to investigational drug or device
- Cardiac event and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) and/or valvular repair/replacement prior to CTCA
- Glomerular Filtration Rate ≤ 30mL/min
- Known allergy to iodinated contrast agent
- Contraindications to beta blockers or nitroglycerin or adenosine
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Retrospective
4000 patients who were clinically evaluated by CTCA from 1 Jan 2007 to 31 Oct 2017.
|
CTCA is performed as part of routine care procedure.
|
Prospective
4000 patients who are clinically evaluated by CTCA.
|
CTCA is performed as part of routine care procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AI precision toolkits: AI stenosis reporting
Time Frame: baseline
|
Stenosis reporting: Severity of stenosis and accurate anatomical localization of stenosis. The significance of a stenosis is determined by visual estimation of the maximal grade of luminal narrowing caused by the plaque. As recommended in SCCT guideline (Leipsic et al., 2014) , coronary stenosis can be graded as minimal, mild, moderate, severe and total occluded separately. Following the guideline, a stenosis will be classified as obstructive and non-obstructive. The location of the stenosis uses the SCCT model (Leipsic et al., 2014) |
baseline
|
AI precision toolkits: Agatston scoring
Time Frame: baseline
|
Agatston scoring: Agatston scoring of calcified plaque.
As recommended in SCCT clinical practical guidelines (Leipsic et al., 2014), Agatston scoring programs generally identify pixels that exceed 130 HU as a level corresponding to calcium on a non-contrast study (Agatston et al., 1990) .
The reader needs to identify each lesion discrete calcific focus) in each vessel distribution.
The summed score for each vessel is generated by the scoring program based on an area-density (Agatston score) (Agatston et al., 1990) measurement of each calcified focus.
The total coronary Agatston score is the sum of all calcified lesions in all coronary beds.
|
baseline
|
AI precision toolkits: Plaque
Time Frame: baseline
|
Plaque analysis: Plaque volume, burden, type and anatomical locations.
Coronary segmentation and plaque analysis is performed for segments with diameter ≥1.5 mm.
Location of plaque uses the SCCT model (Leipsic et al., 2014).
For each plaque, the reader marks its start-and end-points, quantifies plaque area,volume and plaque burden, and specifies its type (non-calcified, calcified, or mixed) (Achenbach et al., 2004) .
Additionally, non-calcified plaque can be further divided into low attenuation plaque (LAP).
A HU <30 will signify LAP and >30 will signify non-LAP.
|
baseline
|
AI precision toolkits: EAT analysis
Time Frame: baseline
|
EAT analysis: Total volume and anatomical locations.
EAT and pericardial adipose tissue (PAT) are metabolically active fat surrounding the coronary artery and the heart, being associated with increased risk of cardiovascular disease (Villasante et al, 2019) .
EAT can be quantified on non-contrast CT scans.
The annotations on the CT scans are obtained by manually drawing the pericardium first to define the region.
EAT is identified using the adipose tissue attenuation references between -190 and -30 HU (Oikonomou et al., 2018) .
Due to the CT scan noise and changing of attenuation, the HU value of fat can vary, so the final EAT region is verified by an experienced radiologist or cardiologist.
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AI outcome analysis
Time Frame: one to five years from baseline
|
1. Mortality (All-cause and/or cardiovascular)
|
one to five years from baseline
|
AI outcome analysis
Time Frame: one to five years from baseline
|
Major-adverse cardiovascular events (myocardial infarction, stroke, heart failure, revascularisation, arrhythmias, etc)
|
one to five years from baseline
|
AI outcome analysis
Time Frame: one to five years from baseline
|
Re-hospitalisation
|
one to five years from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Liang Zhong, National Heart Centre Singapore
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APOLLO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on CTCA
-
Sandwell & West Birmingham Hospitals NHS TrustRecruiting
-
University of EdinburghNHS Lothian; NHS Greater Glasgow and Clyde; University of Glasgow; Chief Scientist...RecruitingCardiovascular Diseases | Kidney Transplant; ComplicationsUnited Kingdom
-
University of EdinburghUniversity of Sheffield; NHS Lothian; British Heart Foundation; NHS Greater Glasgow...Active, not recruitingCoronary Artery DiseaseUnited Kingdom
-
University of LeicesterNational Heart, Lung, and Blood Institute (NHLBI); University of Oxford; University... and other collaboratorsRecruiting
-
University of BolognaUniversity of Cambridge; Centro per la Lotta Contro l'Infarto - Fondazione...RecruitingCoronary Artery Disease | Inflammation | Atherosclerosis | Acute Coronary SyndromeItaly
-
Queen Mary University of LondonActive, not recruitingContrast-induced Nephropathy | Ischaemic Heart DiseaseUnited Kingdom
-
University College, LondonCompletedCoronary Artery DiseaseUnited Kingdom
-
American College of RadiologyPennsylvania Department of HealthCompletedCoronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
University Hospital Plymouth NHS TrustCompleted
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Herlev HospitalEnrolling by invitationCardiovascular Diseases | Coronary Atherosclerosis and Other Heart DiseaseDenmark